The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.

@article{Athauda2016TheGP,
  title={The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.},
  author={Dilan Athauda and Thomas Foltynie},
  journal={Drug discovery today},
  year={2016},
  volume={21 5},
  pages={802-18}
}
Growing evidence suggests that agonists of the glucagon-like peptide 1 (GLP-1) receptor provide neuroprotection across a range of experimental models of Parkinson's disease (PD) and, recently, a small proof-of-concept, open-label human trial of exenatide in the treatment moderate severity PD appeared to show persistent improvements in motor and cognitive function. The underlying mechanisms of action remain unclear, but as evidence for the potential use of GLP-1 agonists in treating several… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis

Cell transplantation • 2017
View 6 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 248 references

Anti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion

X Du
Mol. Biol. Rep • 2014
View 4 Excerpts
Highly Influenced

Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity.

The Journal of pharmacology and experimental therapeutics • 2010
View 5 Excerpts
Highly Influenced

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.

Proceedings of the National Academy of Sciences of the United States of America • 2009
View 10 Excerpts
Highly Influenced

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron

T Perry
J. Neurosci. Res • 2003
View 6 Excerpts
Highly Influenced

CSF b-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease

M Terrelonge
J. Mol. Neurosci • 2015
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…